
Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.
Key opinion leaders analyze EULAR 2024 updates on gout, chronic inflammation's systemic impact, and gout-chronic kidney disease (CKD) connections, while examining urate-lowering therapies for gout management, particularly in patients with CKD.






